Singular Genomics Systems, Inc. (OMIC): Price and Financial Metrics
OMIC Price/Volume Stats
Current price | $0.57 | 52-week high | $1.58 |
Prev. close | $0.55 | 52-week low | $0.31 |
Day low | $0.57 | Volume | 1,605 |
Day high | $0.57 | Avg. volume | 117,170 |
50-day MA | $0.51 | Dividend yield | N/A |
200-day MA | $0.54 | Market Cap | 41.83M |
OMIC Stock Price Chart Interactive Chart >
OMIC POWR Grades
- Sentiment is the dimension where OMIC ranks best; there it ranks ahead of 47.82% of US stocks.
- OMIC's strongest trending metric is Quality; it's been moving down over the last 46 days.
- OMIC ranks lowest in Quality; there it ranks in the 6th percentile.
OMIC Stock Summary
- SINGULAR GENOMICS SYSTEMS INC's stock had its IPO on May 27, 2021, making it an older stock than just 7.03% of US equities in our set.
- OMIC's price/sales ratio is 13.94; that's higher than the P/S ratio of 92.15% of US stocks.
- Revenue growth over the past 12 months for SINGULAR GENOMICS SYSTEMS INC comes in at 239.22%, a number that bests 97.77% of the US stocks we're tracking.
- Stocks that are quantitatively similar to OMIC, based on their financial statements, market capitalization, and price volatility, are LCTX, FCEL, APLS, NWBO, and LGVN.
- Visit OMIC's SEC page to see the company's official filings. To visit the company's web site, go to singulargenomics.com.
OMIC Valuation Summary
- OMIC's EV/EBIT ratio is -0.8; this is 105.48% lower than that of the median Healthcare stock.
- Over the past 32 months, OMIC's price/earnings ratio has gone up 37.1.
Below are key valuation metrics over time for OMIC.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
OMIC | 2023-12-29 | 13.0 | 0.2 | -0.4 | -0.8 |
OMIC | 2023-12-28 | 13.3 | 0.2 | -0.4 | -0.8 |
OMIC | 2023-12-27 | 12.6 | 0.2 | -0.4 | -0.8 |
OMIC | 2023-12-26 | 11.8 | 0.2 | -0.3 | -0.8 |
OMIC | 2023-12-22 | 12.1 | 0.2 | -0.3 | -0.8 |
OMIC | 2023-12-21 | 11.9 | 0.2 | -0.3 | -0.8 |
OMIC Price Target
For more insight on analysts targets of OMIC, see our OMIC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $30.33 | Average Broker Recommendation | 1.6 (Moderate Buy) |
Singular Genomics Systems, Inc. (OMIC) Company Bio
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
Latest OMIC News From Around the Web
Below are the latest news stories about SINGULAR GENOMICS SYSTEMS INC that investors may wish to consider to help them evaluate OMIC as an investment opportunity.
Singular Genomics Systems Founder Acquires 4.6% More StockEven if it's not a huge purchase, we think it was good to see that Eli Glezer, the Founder of Singular Genomics... |
Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q3 2023 Earnings Call TranscriptSingular Genomics Systems, Inc. (NASDAQ:OMIC) Q3 2023 Earnings Call Transcript November 14, 2023 Singular Genomics Systems, Inc. beats earnings expectations. Reported EPS is $-0.31, expectations were $-0.38. Operator: Greetings. Welcome to the Singular Genomics Systems, Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions]. I will now turn the conference over to your host, Philip […] |
Q3 2023 Singular Genomics Systems Inc Earnings CallQ3 2023 Singular Genomics Systems Inc Earnings Call |
Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial ResultsSAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023. “We shipped five G4 systems in the third quarter, our highest quarterly total yet, launched Max Read flow cell kits for single cell sequencing, and saw o |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning! |
OMIC Price Returns
1-mo | 4.13% |
3-mo | 39.36% |
6-mo | 45.04% |
1-year | -55.81% |
3-year | N/A |
5-year | N/A |
YTD | 23.89% |
2023 | -77.11% |
2022 | -82.61% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...